The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: The experience of the BIG 02-98 trial

Evandro De Azambuja, Worta McCaskill-Stevens, Prudence Francis, Emmanuel Quinaux, John P A Crown, Malou Vicente, Rosa Giuliani, Bo Nordenskjöld, Jorge Gutiérez, Michael Andersson, Mireia Margeli Vila, Raimund Jakesz, Jan Demol, Joanna Dewar, Armando Santoro, Ana Lluch, Steven Olsen, Richard D. Gelber, Angelo Di Leo, Martine Piccart-Gebhart

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Background: Obesity has been shown to be an indicator of poor prognosis for patients with primary breast cancer (BC) regardless of the use of adjuvant systemic therapy. Patients and methods: This is a retrospective analysis of 2,887 node-positive BC patients enrolled in the BIG 02-98 adjuvant study, a randomised phase III trial whose primary objective was to evaluate disease-free survival (DFS) by adding docetaxel to doxorubicin-based chemotherapy. In the current analysis, the effect of body mass index (BMI) on DFS and overall survival (OS) was assessed. BMI was obtained before the first cycle of chemotherapy. Obesity was defined as a BMI ≥ 30 kg/m2. Results: In total 547 (19%) patients were obese at baseline, while 2,340 (81%) patients were non-obese. Estimated 5-year OS was 87.5% for non-obese and 82.9% for obese patients (HR 1.34; P = 0.013). Estimated 5-years DFS was 75.9% for non-obese and 70.0% for obese patients (HR 1.20; P = 0.041). In a multivariate model, obesity remained an independent prognostic factor for OS and DFS. Conclusions: In this study, obesity was associated with poorer outcome in node-positive BC patients. Given the increasing prevalence of obesity worldwide, more research on improving the treatment of obese BC patients is needed.

Original languageEnglish
Pages (from-to)145-153
Number of pages9
JournalBreast Cancer Research and Treatment
Volume119
Issue number1
DOIs
Publication statusPublished - Jan 2010

Fingerprint

docetaxel
Adjuvant Chemotherapy
Doxorubicin
Disease-Free Survival
Body Mass Index
Breast Neoplasms
Obesity
Survival
Drug Therapy

Keywords

  • Adjuvant chemotherapy
  • BMI
  • Breast cancer
  • Docetaxel
  • Node-positive
  • Obesity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy : The experience of the BIG 02-98 trial. / De Azambuja, Evandro; McCaskill-Stevens, Worta; Francis, Prudence; Quinaux, Emmanuel; Crown, John P A; Vicente, Malou; Giuliani, Rosa; Nordenskjöld, Bo; Gutiérez, Jorge; Andersson, Michael; Vila, Mireia Margeli; Jakesz, Raimund; Demol, Jan; Dewar, Joanna; Santoro, Armando; Lluch, Ana; Olsen, Steven; Gelber, Richard D.; Di Leo, Angelo; Piccart-Gebhart, Martine.

In: Breast Cancer Research and Treatment, Vol. 119, No. 1, 01.2010, p. 145-153.

Research output: Contribution to journalArticle

De Azambuja, E, McCaskill-Stevens, W, Francis, P, Quinaux, E, Crown, JPA, Vicente, M, Giuliani, R, Nordenskjöld, B, Gutiérez, J, Andersson, M, Vila, MM, Jakesz, R, Demol, J, Dewar, J, Santoro, A, Lluch, A, Olsen, S, Gelber, RD, Di Leo, A & Piccart-Gebhart, M 2010, 'The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: The experience of the BIG 02-98 trial', Breast Cancer Research and Treatment, vol. 119, no. 1, pp. 145-153. https://doi.org/10.1007/s10549-009-0512-0
De Azambuja, Evandro ; McCaskill-Stevens, Worta ; Francis, Prudence ; Quinaux, Emmanuel ; Crown, John P A ; Vicente, Malou ; Giuliani, Rosa ; Nordenskjöld, Bo ; Gutiérez, Jorge ; Andersson, Michael ; Vila, Mireia Margeli ; Jakesz, Raimund ; Demol, Jan ; Dewar, Joanna ; Santoro, Armando ; Lluch, Ana ; Olsen, Steven ; Gelber, Richard D. ; Di Leo, Angelo ; Piccart-Gebhart, Martine. / The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy : The experience of the BIG 02-98 trial. In: Breast Cancer Research and Treatment. 2010 ; Vol. 119, No. 1. pp. 145-153.
@article{03fc71f6f6cf4a4ba021bdff6d696b9d,
title = "The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: The experience of the BIG 02-98 trial",
abstract = "Background: Obesity has been shown to be an indicator of poor prognosis for patients with primary breast cancer (BC) regardless of the use of adjuvant systemic therapy. Patients and methods: This is a retrospective analysis of 2,887 node-positive BC patients enrolled in the BIG 02-98 adjuvant study, a randomised phase III trial whose primary objective was to evaluate disease-free survival (DFS) by adding docetaxel to doxorubicin-based chemotherapy. In the current analysis, the effect of body mass index (BMI) on DFS and overall survival (OS) was assessed. BMI was obtained before the first cycle of chemotherapy. Obesity was defined as a BMI ≥ 30 kg/m2. Results: In total 547 (19{\%}) patients were obese at baseline, while 2,340 (81{\%}) patients were non-obese. Estimated 5-year OS was 87.5{\%} for non-obese and 82.9{\%} for obese patients (HR 1.34; P = 0.013). Estimated 5-years DFS was 75.9{\%} for non-obese and 70.0{\%} for obese patients (HR 1.20; P = 0.041). In a multivariate model, obesity remained an independent prognostic factor for OS and DFS. Conclusions: In this study, obesity was associated with poorer outcome in node-positive BC patients. Given the increasing prevalence of obesity worldwide, more research on improving the treatment of obese BC patients is needed.",
keywords = "Adjuvant chemotherapy, BMI, Breast cancer, Docetaxel, Node-positive, Obesity",
author = "{De Azambuja}, Evandro and Worta McCaskill-Stevens and Prudence Francis and Emmanuel Quinaux and Crown, {John P A} and Malou Vicente and Rosa Giuliani and Bo Nordenskj{\"o}ld and Jorge Guti{\'e}rez and Michael Andersson and Vila, {Mireia Margeli} and Raimund Jakesz and Jan Demol and Joanna Dewar and Armando Santoro and Ana Lluch and Steven Olsen and Gelber, {Richard D.} and {Di Leo}, Angelo and Martine Piccart-Gebhart",
year = "2010",
month = "1",
doi = "10.1007/s10549-009-0512-0",
language = "English",
volume = "119",
pages = "145--153",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "1",

}

TY - JOUR

T1 - The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy

T2 - The experience of the BIG 02-98 trial

AU - De Azambuja, Evandro

AU - McCaskill-Stevens, Worta

AU - Francis, Prudence

AU - Quinaux, Emmanuel

AU - Crown, John P A

AU - Vicente, Malou

AU - Giuliani, Rosa

AU - Nordenskjöld, Bo

AU - Gutiérez, Jorge

AU - Andersson, Michael

AU - Vila, Mireia Margeli

AU - Jakesz, Raimund

AU - Demol, Jan

AU - Dewar, Joanna

AU - Santoro, Armando

AU - Lluch, Ana

AU - Olsen, Steven

AU - Gelber, Richard D.

AU - Di Leo, Angelo

AU - Piccart-Gebhart, Martine

PY - 2010/1

Y1 - 2010/1

N2 - Background: Obesity has been shown to be an indicator of poor prognosis for patients with primary breast cancer (BC) regardless of the use of adjuvant systemic therapy. Patients and methods: This is a retrospective analysis of 2,887 node-positive BC patients enrolled in the BIG 02-98 adjuvant study, a randomised phase III trial whose primary objective was to evaluate disease-free survival (DFS) by adding docetaxel to doxorubicin-based chemotherapy. In the current analysis, the effect of body mass index (BMI) on DFS and overall survival (OS) was assessed. BMI was obtained before the first cycle of chemotherapy. Obesity was defined as a BMI ≥ 30 kg/m2. Results: In total 547 (19%) patients were obese at baseline, while 2,340 (81%) patients were non-obese. Estimated 5-year OS was 87.5% for non-obese and 82.9% for obese patients (HR 1.34; P = 0.013). Estimated 5-years DFS was 75.9% for non-obese and 70.0% for obese patients (HR 1.20; P = 0.041). In a multivariate model, obesity remained an independent prognostic factor for OS and DFS. Conclusions: In this study, obesity was associated with poorer outcome in node-positive BC patients. Given the increasing prevalence of obesity worldwide, more research on improving the treatment of obese BC patients is needed.

AB - Background: Obesity has been shown to be an indicator of poor prognosis for patients with primary breast cancer (BC) regardless of the use of adjuvant systemic therapy. Patients and methods: This is a retrospective analysis of 2,887 node-positive BC patients enrolled in the BIG 02-98 adjuvant study, a randomised phase III trial whose primary objective was to evaluate disease-free survival (DFS) by adding docetaxel to doxorubicin-based chemotherapy. In the current analysis, the effect of body mass index (BMI) on DFS and overall survival (OS) was assessed. BMI was obtained before the first cycle of chemotherapy. Obesity was defined as a BMI ≥ 30 kg/m2. Results: In total 547 (19%) patients were obese at baseline, while 2,340 (81%) patients were non-obese. Estimated 5-year OS was 87.5% for non-obese and 82.9% for obese patients (HR 1.34; P = 0.013). Estimated 5-years DFS was 75.9% for non-obese and 70.0% for obese patients (HR 1.20; P = 0.041). In a multivariate model, obesity remained an independent prognostic factor for OS and DFS. Conclusions: In this study, obesity was associated with poorer outcome in node-positive BC patients. Given the increasing prevalence of obesity worldwide, more research on improving the treatment of obese BC patients is needed.

KW - Adjuvant chemotherapy

KW - BMI

KW - Breast cancer

KW - Docetaxel

KW - Node-positive

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=72449200565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72449200565&partnerID=8YFLogxK

U2 - 10.1007/s10549-009-0512-0

DO - 10.1007/s10549-009-0512-0

M3 - Article

C2 - 19731015

AN - SCOPUS:72449200565

VL - 119

SP - 145

EP - 153

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -